Matthew Kulke

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3555-61. 2006
  2. doi request reprint Systemic therapy for advanced pancreatic neuroendocrine tumors
    Matthew H Kulke
    Program in Neuroendocrine and Carcinoid Tumors, Dana Farber Brigham and Women s Cancer Center, Boston, MA, USA
    Semin Oncol 40:75-83. 2013
  3. ncbi request reprint Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer
    Matthew H Kulke
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Thorac Cardiovasc Surg 127:1579-86. 2004
  4. pmc Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 27:5506-12. 2009
  5. ncbi request reprint A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Institute, Boston, Massachusetts, USA
    Dig Dis Sci 51:1033-8. 2006
  6. pmc O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:338-45. 2009
  7. pmc NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston MA 02115, USA
    Pancreas 39:735-52. 2010
  8. ncbi request reprint Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:401-6. 2006
  9. doi request reprint Activity of sunitinib in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:3403-10. 2008
  10. ncbi request reprint Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:4787-92. 2007

Detail Information

Publications63

  1. ncbi request reprint Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3555-61. 2006
    ..We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors...
  2. doi request reprint Systemic therapy for advanced pancreatic neuroendocrine tumors
    Matthew H Kulke
    Program in Neuroendocrine and Carcinoid Tumors, Dana Farber Brigham and Women s Cancer Center, Boston, MA, USA
    Semin Oncol 40:75-83. 2013
    ..Recently, the biologically targeted agents everolimus and sunitinib were approved for use in patients with metastatic disease. Novel agents, as well as novel drug combinations, are currently under investigation...
  3. ncbi request reprint Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer
    Matthew H Kulke
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Thorac Cardiovasc Surg 127:1579-86. 2004
    ....
  4. pmc Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 27:5506-12. 2009
    ..We explored the efficacy and toxicity of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in a multi-institutional, randomized, phase II study...
  5. ncbi request reprint A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Institute, Boston, Massachusetts, USA
    Dig Dis Sci 51:1033-8. 2006
    ..4 months. We conclude that while the combination of irinotecan and cisplatin may have activity in aggressive neuroendocrine tumor subtypes, this combination is inactive in patients with well-differentiated neuroendocrine tumors...
  6. pmc O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:338-45. 2009
    ..We evaluated the prevalence of MGMT deficiency in neuroendocrine tumors and correlated MGMT deficiency with treatment response to temozolomide-based regimens...
  7. pmc NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston MA 02115, USA
    Pancreas 39:735-52. 2010
    ..We provide an overview of well-differentiated NETs of the stomach and pancreas and describe consensus guidelines for the treatment of patients with these malignancies...
  8. ncbi request reprint Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:401-6. 2006
    ..We evaluated the efficacy of an oral regimen of temozolomide and thalidomide in patients with metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors...
  9. doi request reprint Activity of sunitinib in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:3403-10. 2008
    ..We evaluated the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients...
  10. ncbi request reprint Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:4787-92. 2007
    ..We evaluated an oral regimen of capecitabine and erlotinib in patients with advanced pancreatic cancer who had experienced treatment failure with standard first-line therapy with gemcitabine...
  11. ncbi request reprint Gastrointestinal neuroendocrine tumors: a role for targeted therapies?
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Endocr Relat Cancer 14:207-19. 2007
    ..Ongoing randomized studies should help better define the role these and other targeted agents will play in the future treatment of patients with this disease...
  12. ncbi request reprint A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Invest 24:346-50. 2006
    ..9 months and the median overall survival time was 7.8 months. We conclude that vinorelbine has minimal toxicity but only minor antitumor activity in patients with advanced gastroesophageal adenocarcinoma...
  13. ncbi request reprint New developments in the treatment of gastrointestinal neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 9:177-83. 2007
    ..Continued investigation of these agents should render a better understanding of their efficacy in patients with advanced neuroendocrine tumors...
  14. ncbi request reprint Advances in the treatment of neuroendocrine tumors
    Matthew Kulke
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Curr Treat Options Oncol 6:397-409. 2005
    ..Larger, randomized trials, along with the evaluation of surrogate endpoints of biologic activity, may be necessary to establish the potential clinical benefit of these novel agents...
  15. doi request reprint A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 68:293-300. 2011
    ..We performed a prospective, phase II study of 2ME2, administered in combination with bevacizumab, in patients with advanced carcinoid tumors...
  16. ncbi request reprint Metastatic pancreatic cancer
    Matthew H Kulke
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Treat Options Oncol 3:449-57. 2002
    ..Palliative procedures, such as biliary or duodenal stenting and celiac plexus blockade, should be considered in conjunction with systemic therapy in patients with specific complications from pancreatic cancer...
  17. ncbi request reprint Recent developments in the pharmacological treatment of advanced pancreatic cancer
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Investig Drugs 12:983-92. 2003
    ..A number of novel chemotherapeutic and biological agents also appear promising and are likely to play a future role in the treatment of patients with advanced pancreatic cancer...
  18. ncbi request reprint Neuroendocrine tumours: clinical presentation and management of localized disease
    Matthew H Kulke
    Dana Farber Cancer Institute and Harvard Medical School, Department of Medical Oncology, Boston, MA 0215, USA
    Cancer Treat Rev 29:363-70. 2003
    ..In recent years, improved diagnostic techniques, increased recognition of neuroendocrine tumour subtypes, and new therapeutic modalities have enhanced clinicians' ability to detect and appropriately treat these malignancies...
  19. ncbi request reprint Advanced pancreatic cancer: is there a role for combination therapy?
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 3:729-39. 2003
    ..Increasingly, attention has turned to a number of novel chemotherapeutic and biologic agents that appear promising and are likely to play an important future role in the treatment of patients with this disease...
  20. pmc Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston MA, USA
    J Hematol Oncol 4:29. 2011
    ....
  21. ncbi request reprint A phase II study of docetaxel in patients with metastatic carcinoid tumors
    Matthew H Kulke
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Invest 22:353-9. 2004
    ..Twenty-one patients with metastatic carcinoid tumors were treated with docetaxel. Although the treatment was well tolerated, no objective radiologic responses were observed. Novel, more effective agents are needed for this disease...
  22. ncbi request reprint A Phase II trial of gemcitabine for metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer 101:934-9. 2004
    ..Gemcitabine is generally well tolerated and possesses demonstrated activity against a wide range of malignancies. The authors assessed the efficacy of gemcitabine in the treatment of patients with metastatic neuroendocrine tumors...
  23. ncbi request reprint Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:1892-7. 2006
    ..To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer...
  24. ncbi request reprint A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer
    David P Ryan
    Dana Farber Partners Cancer Care Gastrointestinal Cancer Center, Brigham and Women s Hospital, Dana Farber Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer Invest 21:505-11. 2003
    ....
  25. ncbi request reprint A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Invest 24:229-34. 2006
    ..The use of doxorubicin as an alternative to epirubicin in the ECF regimen has not been evaluated...
  26. ncbi request reprint A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer
    Matthew H Kulke
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer J 8:395-9. 2002
    ..We therefore assessed the efficacy of troglitazone in the treatment of metastatic colon cancer in humans...
  27. doi request reprint DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor
    Lynn Kristin Bracht
    Center for Neuro Oncology, Boston, MA, USA
    J Clin Oncol 26:4843-4. 2008
  28. ncbi request reprint Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Dig Dis Sci 53:564-70. 2008
    ....
  29. ncbi request reprint A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma
    David P Ryan
    Gastrointestinal Cancer Center, Dana Farber Partners Cancer Care, Boston, Massachusetts, USA
    Cancer 94:97-103. 2002
    ..Chemotherapy with gemcitabine is the standard first-line treatment. In a Phase II trial at one academic cancer center, the clinical safety and activity of combining gemcitabine and docetaxel were assessed...
  30. ncbi request reprint Progress in the treatment of neuroendocrine tumors
    Jennifer A Chan
    Gastrointestinal Cancer Center, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 11:193-9. 2009
    ..Additionally, agents targeting the vascular endothelial growth factor pathway and mammalian target of rapamycin have shown preliminary evidence of activity and are currently being evaluated in large randomized studies...
  31. ncbi request reprint A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Oncologist 10:392-8. 2005
    ..Therefore, we performed a phase II study using the combination of epirubicin and thalidomide in patients with unresectable and metastatic HCC...
  32. doi request reprint Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver
    Shantanu K Gaur
    Brigham and Women s Hospital, Angiography and Interventional Radiology, 75 Francis Street, Boston, MA 02115, USA
    Cardiovasc Intervent Radiol 34:566-72. 2011
    ....
  33. ncbi request reprint A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Dig Dis Sci 50:2218-23. 2005
    ..When used as a single-agent, a tri-weekly schedule may be preferable for this patient population...
  34. pmc Phase II study of pemetrexed in patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Dana 1220, Boston, MA, 02115, USA
    Cancer Chemother Pharmacol 66:961-8. 2010
    ..Pemetrexed is a multitargeted antifolate with activity in tumor types not significantly responsive to other antifolates. We evaluated the efficacy of pemetrexed in a phase II study of patients with advanced neuroendocrine tumors...
  35. pmc Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma
    Rihong Zhai
    Department of Environmental Health, Harvard School of Public Health, 665 Huntington Ave, Boston, MA 02115, USA
    J Clin Oncol 28:2445-51. 2010
    ..However, how multiple factors jointly affect EA risk remains unclear...
  36. pmc Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk
    Rihong Zhai
    Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
    Carcinogenesis 29:2330-4. 2008
    ..70; 95% CI, 1.04-2.73; P = 0.034). These results suggested that cigarette smoking modifies the association between VEGF polymorphisms and EA risk among Caucasians...
  37. ncbi request reprint Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 11:6650-6. 2005
    ..Abnormalities of EGFR and related pathways may have an effect on responsiveness of advanced colorectal cancer to combination chemotherapy with gefitinib...
  38. ncbi request reprint Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors
    Thomas E Clancy
    Department of Surgery, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Dig Dis Sci 51:877-84. 2006
    ..Close monitoring of alkaline phosphatase levels may be useful when considering initiation or changes of therapy in patients with metastatic neuroendocrine tumors...
  39. ncbi request reprint CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Virchows Arch 450:529-37. 2007
    ..Additional studies are necessary to examine the role of DNA methylation in treatment efficacy...
  40. ncbi request reprint Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
    Andrew X Zhu
    Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 59:285-93. 2007
    ....
  41. pmc Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization
    Pedram Heidari
    Authors Affiliations Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School and Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
    Cancer Res 73:6865-73. 2013
    ..Clinical trials validating this approach are warranted...
  42. pmc Pheochromocytoma and paraganglioma: imaging characteristics
    Juan C Baez
    Department of Radiology, Brigham and Women s Hospital, Boston, MA, USA
    Cancer Imaging 12:153-62. 2012
    ..Knowledge of the diverse appearance of pheochromocytomas and paragangliomas can result in early initial diagnosis or detection of disease recurrence thereby affecting patient management and prognosis...
  43. ncbi request reprint Carcinoid tumors
    Chandrajit P Raut
    Harvard Medical School, Boston, Massachusetts, USA
    Curr Probl Surg 43:383-450. 2006
  44. doi request reprint Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing
    Jin Li
    Department of Radiation Oncology, Divisions of Genomic Stability and DNA Repair, Physics and Radiation Therapy, Room JF514, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nat Med 14:579-84. 2008
    ..COLD-PCR will transform the capabilities of PCR-based genetic testing, including applications in cancer, infectious diseases and prenatal identification of fetal alleles in maternal blood...
  45. doi request reprint High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Genes Chromosomes Cancer 47:591-603. 2008
    ..This detailed study of an uncommon neoplasm provides a basis to investigate putative oncogenes and tumor suppressor genes in intestinal carcinoid tumors...
  46. doi request reprint Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis
    Eva Maria Duerr
    Gastrointestinal Unit, Department of Medicine, Cancer Center, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA 02114, USA
    Endocr Relat Cancer 15:243-56. 2008
    ..This suggests that molecular profiling may enhance tumor classification schemes. Potential gene targets have also been identified, and PDGFR and RET are candidates that may represent novel therapeutic targets...
  47. pmc Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth
    Kotoyo Fujiki
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Gastroenterology 135:907-16, 916.e1-2. 2008
    ..The molecular alterations that underlie carcinoid tumor pathogenesis remain poorly defined. The homeobox gene HOXC6 was highly up-regulated in human gastrointestinal carcinoid tumors, and we sought to define its pathogenic role...
  48. ncbi request reprint Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:8453-60. 2005
    ..Although several comprehensive dietary questionnaires have been validated and calibrated in healthy populations, similar studies have not been performed among cancer patients...
  49. pmc A Large-scale genetic association study of esophageal adenocarcinoma risk
    Chen Yu Liu
    Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
    Carcinogenesis 31:1259-63. 2010
    ....
  50. ncbi request reprint Clinical presentation and management of carcinoid tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115 0684, USA
    Hematol Oncol Clin North Am 21:433-55; vii-viii. 2007
    ..Preliminary reports of activity associated with agents targeting the vascular endothelial growth factor pathway suggest that such strategies may play a role in the future treatment of patients who have this disease...
  51. ncbi request reprint Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide
    Abraham B Schwarzberg
    Harvard Medical School, Boston, Massachusetts, USA
    Cancer Invest 25:249-55. 2007
    ..Prophylaxis for Pneumocystis jiroveci pneumonia and varicella-zoster, as well as cytomegalovirus monitoring, should be considered in patients receiving temozolomide-based treatment...
  52. doi request reprint Somatic mutation of CDKN1B in small intestine neuroendocrine tumors
    JOSHUA M FRANCIS
    1 Broad Institute, Cambridge, Massachusetts, USA 2 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA 3
    Nat Genet 45:1483-6. 2013
    ....
  53. ncbi request reprint Antiprimer quenching-based real-time PCR and its application to the analysis of clinical cancer samples
    Jin Li
    Department of Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Clin Chem 52:624-33. 2006
    ..We present a novel quantitative PCR technology that combines the advantages of existing methods and allows versatile and flexible nucleic acid target quantification in clinical samples of widely different origin and quality...
  54. ncbi request reprint Emerging therapies for the treatment of patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Dana Farber Cancer Institute, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Emerg Drugs 12:253-70. 2007
    ..Ongoing randomized studies should help better define the role these agents will play in the future treatment of patients with this disease...
  55. ncbi request reprint Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinoma
    Ross L Levine
    Dana Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA 02115, USA
    Clin Adv Hematol Oncol 1:99-100; discussion 100. 2003
  56. pmc Whole genome amplification of plasma-circulating DNA enables expanded screening for allelic imbalance in plasma
    Jin Li
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Brigham and Women s Hospital, Level L2, Radiation Therapy, 75 Francis St, Boston, MA 02115, USA
    J Mol Diagn 8:22-30. 2006
    ....
  57. doi request reprint F-18 FDG PET/CT in the diagnosis and management of a pericardiac paraganglioma
    Niall Sheehy
    Department of Radiology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Nucl Med 33:545-6. 2008
  58. ncbi request reprint Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors
    A David McCollum
    Baylor University Medical Center Charles A Sammons Cancer Center, Dallas, Texas 75246, USA
    Am J Clin Oncol 27:485-8. 2004
    ..However, a recent review failed to confirm high antitumor activity in patients with advanced PETs...
  59. ncbi request reprint Combination chemotherapy for advanced pancreatic cancer--has its time finally come?
    Matthew H Kulke
    Lancet Oncol 6:352-3. 2005
  60. ncbi request reprint The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer
    A David McCollum
    Texas Oncology, PA, and Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Am J Clin Oncol 29:40-4. 2006
    ..We conducted a multicenter, phase II study to examine the combination of capecitabine and thalidomide (Cape/Thal) in patients with refractory metastatic CRC...
  61. ncbi request reprint Neuroendocrine tumors
    Orlo H Clark
    Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    J Natl Compr Canc Netw 4:102-38. 2006
  62. pmc Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Clin Cancer Res 12:4283-7. 2006
    ..Given recent reports of TKI-responsive cases of esophageal and pancreatic cancer, this study was designed to determine the prevalence of EGFR mutations in these gastrointestinal cancers...
  63. doi request reprint A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies
    Penelope A Bradbury
    Princess Margaret Hospital Ontario Cancer Institute, 610 University Avenue, Toronto, Ontario, Canada
    Cancer Epidemiol Biomarkers Prev 17:204-11. 2008
    ..Using clinical trial and epidemiologic methods, we assessed the quality of prognostic and outcomes data obtainable from a large case-control study of lung cancer...